In 2022, the World Health Organization declared an atypical outbreak of monkeypox (Mpox), which has caused approximately 30,000 cases of Mpox infection within the United States as of April 2023. Mpox represents a current threat to public health, and there is an immediate need for an effective vaccine. To address this, NIAID has developed a vaccine approach comprising virus-like nanoparticles coated with modified Mpox proteins.
Hepatitis C virus (HCV) is a major global health problem with an estimated 58 million infections in 2019. However, most HCV infections go undiagnosed due to the lack of clinical symptoms or for lack of access to simple and affordable diagnostic testing. It is estimated that only 21% and 61% of people with a chronic HCV infection have been diagnosed, worldwide and in the United States, respectively.
Henipaviruses are RNA viruses containing two high consequence human pathogens: Nipah virus (NiV) and Hendra virus (HeV). Both NiV and HeV infection in humans can result in severe respiratory disease and/or severe neurological manifestations, with mortality rates as high as 80%. There are currently no FDA-approved vaccines or therapeutics, and both NiV and HeV are considered dangerous emerging human pathogens with pandemic potential.
Fentanyl is a synthetic opioid drug approved by the Food and Drug Administration for use as an analgesic (pain relief) and anesthetic. However, synthetic opioids, such as fentanyl, are prone to abuse and are the primary drivers of overdose related deaths in the United States. As little as two milligrams of fentanyl can be lethal. Furthermore, structural variants of fentanyl, often mixed with other drugs or counterfeit pills are illegally distributed without the user’s knowledge.
Treatment for human tuberculosis (TB) and other granulomatous diseases would benefit from high- throughput screening (HTS)-compatible platform replicating physiological conditions in hallmark granuloma lesions.
Pre-exposure prophylaxis (PrEP) is a critical component in the fight against HIV but is only effective if persons prescribed PrEP are adhering to the regimens to maintain appropriate drug levels. As PrEP regimens have moved from daily pills to longer lasting injections, the ability to quickly measure and monitor the circulating drug levels of PrEP drugs has increased importance.
Despite four decades of intensive research, a safe and effective HIV-1 vaccine remains elusive due to the extreme difficulty in eliciting broadly neutralizing antibodies (bNAbs), which recognize and block HIV-1 from entering healthy cells. Only rare natural HIV-1 envelopes (Envs) promote the activation and expansion of naive B cells expressing unmutated germline antibodies of various bNAb lineages, but they typically do so for a single lineage for the same neutralization site.